Cardimet MR

Cardimet MR35 mg

Tablet

Trimetazidine Dihydrochloride

Eskayef Bangladesh Ltd.

Product Code : 2853
MRP 80.00
10% Off
Best PriceTk
/
1
Section

Alternatives

See All
Product Image
8% Off

Vastarel MR35 mg

Trimetazidine Dihydrochloride

Servier Bangladesh Operation

276.00
300.00
Add to cart
Product Image
10% Off

Metacard MR35 mg

Trimetazidine Dihydrochloride

Aristopharma Ltd.

126.00
140.00
Add to cart
Product Image
10% Off

Vestar MR35 mg

Trimetazidine Dihydrochloride

Healthcare Pharmacuticals Ltd.

72.00
80.00
Add to cart
Product Image
10% Off

Angivent MR35 mg

Trimetazidine Dihydrochloride

Square Pharmaceuticals Ltd.

72.00
80.00
Add to cart
Product Image
10% Off

Antoris MR35 mg

Trimetazidine Dihydrochloride

Opsonin Pharma Ltd.

132.30
147.00
Add to cart
Product Image
10% Off

Metavas MR35 mg

Trimetazidine Dihydrochloride

NIPRO JMI Pharma Ltd.

72.00
80.00
Add to cart
Product Image
10% Off

Metazine MR35 mg

Trimetazidine Dihydrochloride

Beximco Pharmaceuticals Ltd.

81.00
90.00
Add to cart
Product Image
10% Off

Feelnor MR35 mg

Trimetazidine Dihydrochloride

Incepta Pharmaceuticals Ltd.

60.75
67.50
Add to cart
Product Image
10% Off

Trimet-MR35 mg

Trimetazidine Dihydrochloride

Drug International Ltd.

88.20
98.00
Add to cart
Product Image
10% Off

Angivas MR35 mg

Trimetazidine Dihydrochloride

Popular Pharmaceuticals Ltd.

4.50
5.00
Add to cart
Product Image
10% Off

Angirid MR35 mg

Trimetazidine Dihydrochloride

ACME Laboratories Ltd.

52.20
58.00
Add to cart
Product Image
7% Off

Trangit MR35 mg

Trimetazidine Dihydrochloride

SANDOZ (A Novartis Division)

107.68
115.78
Add to cart
Product Image
10% Off

Trimacontin35 mg

Trimetazidine Dihydrochloride

Mundipharma (BD) Pvt. Ltd.

8.10
9.00
Add to cart
Product Image
10% Off

Trangina MR35 mg

Trimetazidine Dihydrochloride

Biopharma Laboratories Ltd.

54.00
60.00
Add to cart
Product Image
10% Off

Angimet MR35 mg

Trimetazidine Dihydrochloride

Orion Pharma Ltd.

5.40
6.00
Add to cart
Product Image
10% Off

Anginox MR35 mg

Trimetazidine Dihydrochloride

General Pharmaceuticals Ltd.

5.40
6.00
Add to cart
Product Image
10% Off

Angitrim MR35 mg

Trimetazidine Dihydrochloride

Globe Pharmaceuticals Ltd.

5.40
6.00
Add to cart
Product Image
10% Off

Vaspec MR35 mg

Trimetazidine Dihydrochloride

Navana Pharmaceuticals Ltd.

5.40
6.00
Add to cart
Section

Medicine overview

Indications of Cardimet MR 35 mg

Cardimet MR 35 mg is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled by or intolerant to first-line antianginal therapies.

Theropeutic Class

Other Anti-anginal & Anti-ischaemic drugs

Pharmacology

Cardimet MR 35 mg is the first 3- keto acyl CoA thiolase inhibitor (KAT), a metabolic anti-ischemic agent with proven benefits for all coronary patients. Cardimet MR 35 mg inhibits fatty acid pathway by inhibiting 3-keto acyl CoA thiolase enzyme and transfers oxygen to glucose pathway. Since glucose pathway is more efficient in producing energy, the same oxygen produces more energy and makes the heart more active. Moreover, the aerobic oxidation of glucose stops production of lactic acid, which prevents angina pectoris.

Dosage & Administration of Cardimet MR 35 mg

The recommended dose of Trimetazidine is 35 mg twice daily or 20 mg tablet thrice daily during meals. The benefit of the treatment should be assessed after three months and Trimetazidine should be discontinued if there is no treatment response.

Dosage of Cardimet MR 35 mg

The recommended dose of Trimetazidine is 35 mg twice daily or 20 mg tablet thrice daily during meals. The benefit of the treatment should be assessed after three months and Trimetazidine should be discontinued if there is no treatment response.

Interaction of Cardimet MR 35 mg

No drug interaction so far has been reported. In particular, no interaction has been reported with beta-blockers, calcium antagonists, nitrates, heparin, hypolipidemic agents or digitalis preparation.

Contraindications

Trimetazidine is contraindicated in patients who have hypersensitivity to the active substance or to any of the excipients. It is also is contraindicated in patients with Parkinson’s disease, parkinsonian symptoms, tremors, restless legs movement disorders, severe renal impairment.

Side Effects of Cardimet MR 35 mg

Trimetazidine is safe and well tolerated. The Common side effects associated with Trimetazidine are dizziness, headache, abdominal pain, diarrhoea, dyspepsia, nausea, vomiting, rash, pruritus, urticaria and asthenia

Pregnancy & Lactation

There is no data on the use of Trimetazidine in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. As a precautionary measure, it is preferable to avoid the use of Trimetazidine during pregnancy. It is unknown whether Trimetazidine is excreted in human milk. A risk to the newborns/infants cannot be excluded. Trimetazidine should not be used during breast-feeding.

Precautions & Warnings

Trimetazidine is not a curative treatment for angina attacks, nor an initial treatment for unstable angina pectoris. It is also not a treatment for myocardial infarction.

Storage Conditions

Keep in a dry place away from light and heat. Keep out of the reach of children.

Drug Classes

Other Anti-anginal & Anti-ischaemic drugs

Mode Of Action

Cardimet MR 35 mg is the first 3- keto acyl CoA thiolase inhibitor (KAT), a metabolic anti-ischemic agent with proven benefits for all coronary patients. Cardimet MR 35 mg inhibits fatty acid pathway by inhibiting 3-keto acyl CoA thiolase enzyme and transfers oxygen to glucose pathway. Since glucose pathway is more efficient in producing energy, the same oxygen produces more energy and makes the heart more active. Moreover, the aerobic oxidation of glucose stops production of lactic acid, which prevents angina pectoris.

Pregnancy

There is no data on the use of Trimetazidine in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. As a precautionary measure, it is preferable to avoid the use of Trimetazidine during pregnancy. It is unknown whether Trimetazidine is excreted in human milk. A risk to the newborns/infants cannot be excluded. Trimetazidine should not be used during breast-feeding.
Disclaimer

The information provided is accurate to our best practices, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy. The absence of specific information about a drug should not be seen as an endorsement. We are not responsible for any consequences resulting from this information, so consult a healthcare professional for any concerns or questions.